Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Considering the environment at the moment these are great q3 results with a 30% increase in net cash from q2. Trajectory is really positive.
Blue, the main point is the result did offer better than the placebo; and more importantly, no matter how cr*p people thinks the results were , they were as good as the current market competitors but without the side effects. That means the market is up for grabs ... 2.4bn in us alone.
Thank god the market has finally closed ! What a cr*p day.
To be honest, there are a lot of ppl (me included) who invested at around 40-45p. Can’t really blame them for realising a profit now and good for them. It’s only real once you bank it. Very confident when the results and presentation are fully digested this is going to go north rapidly.
Sorry. Wrong board!
To be honest, there are a lot of ppl (me included) who invested at around 40-45p. Can’t really blame them for realising a profit now and good for them. It’s only real once you bank it. Very confident when the results are fully digested this is going to go north rapidly.
I’m invested in this - quite heavily now given the share price increase over last two months. Not worried as the presentation gave context that this is potentially a commercial time bomb. I have bought quite a bit more at about 130 just now which I’ll trade as I can’t see things staying like this for more than a day or a couple of days. We’ll see.
Even if this dips it won’t be for long - see my earlier comment re presentation.
I originally said the results are ‘ok, certainly not great’. I’ve listened to the presentation on the website. Key adds are that the efficacy as as good as other drugs on the market but without the side effects; increases the market by a third as can cover its-m subtype; the us market in 2024 est 2.4bn which is an ‘underestimate’; already talking to ‘all the major players in the field’. So, whilst on the face of it the results don’t look exceptional they are good enough to have massive commercial implications. So I correct my original assessment - the results are great.
If you read the rns properly the results are just ok, certainly not great.
I’m very positive about the upcoming results.
However it’s important still to compare like with like. Due to two placings there has been 64% share dilution since December. So on a like for like basis, the December market cap (100p a share) would be about 60p today given the share dilution. So I’m guessing our market cap now is already 250% of that in December. Just estimating but seems logical to me.
Also, in the interview the CEO gave a few weeks ago I got the distinct impression he was downplaying COVID results this year. Did anyone else feel this?
This rns is good news. I just don’t get why there is no expression of pleasure on the outcome within the rns. I’ve re-read is a number of times just in case I’ve misinterpreted something.
Unfortunately , LEK appears to have deteriorating cash flow issues.
Nota, you sure the current bond price is 90? The first google hit has 90 but states delayed data so price is as if 9th Sep. Another site has a significant lower up to date price from the graph but inconveniently they haven’t labelled the axis with the prices so I can only tell it’s lower (cbonds website); even then I can’t really tell if it’s an estimation.
Can someone help me with this bit ... the very last part ... is that saying $200m total over 7 years? Considering financing and tax over that period could be well over half that amount it’s not a massive amount to be distributed to shareholders ... so is the future value mostly in expansion potential ...
the maiden resource alone potentially supports a production rate of 2 million tonnes per annum for seven years for net operating cash flow of c.$70 million p.a. at current metal prices. After initial and sustaining capital expenditure of c.$222 million and c.$46 million respectively, this would indicate an estimated net cash surplus of over $200 million before financing costs and tax
Results are ok, nothing really unexpected. Interesting that krg only commit to ‘review’ the delayed payments rather than actually pay them. Also can anyone clarify why it is a lengthy process to cancel the treasury shares - is it because they would have to realise the loss on these in the accounts (I see a $49m loss which I think is these later in the accounting).